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Atopic dermatitis (AD) is a chronic inflammatory skin disease 
where more than 90% of patients affected are colonized with 
Staphylococcus aureus. In AD, S. aureus δ-toxin is a major viru-
lence factor causing cutaneous inflammation via mast cell degran-
ulation. δ-toxin is controlled by the S. aureus agr quorum sensing 
system, and thus we addressed whether interference with agr sig-
naling would limit skin inflammation. Indeed, treatment of S. aur-
eus with the agr-inhibitor solonamide B (SolB) abolished δ-toxin 
production and reduced skin inflammation in a mouse model of 
inflammatory skin disease, demonstrating the potential of antivir-
ulence therapy in treating S. aureus-induced skin disorders.
Keywords. Staphylococcus aureus; agr  quorum sensing 
inhibition; atopic dermatitis; δ-toxin; antivirulence therapy.
 
Antibiotic resistance is a growing problem and alternative ther-
apeutic strategies have been proposed such as antivirulence 
therapy, where virulence rather than viability is targeted [1]. 
Expression of bacterial virulence factors are often controlled 
by quorum sensing, as is the case in the human pathogen 
Staphylococcus aureus. S. aureus is part of the human commensal 
microbiota, but is also a serious opportunistic pathogen giving 
rise to acute and chronic infections [2]. Worryingly, methicil-
lin-resistant S.  aureus strains are spreading in the community 
and these strains, such as LAC USA300, are characterized by a 
hyperactive agr, the quorum sensing system of S. aureus [3, 4]. 
Agr responds to accumulation of self-produced peptides known 
as autoinducing peptides (AIPs) that bind to AgrC (a 2-compo-
nent sensor histidine kinase) and stimulate the expression of reg-
ulatory RNAIII, the effector molecule of agr [3, 4]. Importantly, 
RNAIII also contains the hld gene, which encodes δ-toxin, a 
known S. aureus virulence factor and member of the cytolytic 
pore-forming secreted peptide family known as the phenol-sol-
uble modulins (PSMs) [3, 4]. Recently, a link between S. aureus 
and acute dermatitis was reported, where δ-toxin was revealed 
as a hyperinducer of mast cell degranulation playing a key role 
in IgE-mediated allergic responses in atopic dermatitis (AD) [5]. 
AD is a chronically relapsing inflammatory skin disorder where 
over 90% of patients are colonized by S. aureus, 25% of which 
are USA300 [6]. Notably, S. aureus isolates from skin lesions of 
AD patients have been shown to produce high levels of δ-toxin 
[5]. Targeting δ-toxin production by S. aureus at sites of coloni-
zation in these patients might thus be of therapeutic value for the 
treatment of AD symptoms related to mast cell hyperinduction.
Several natural compounds have been found to target vir-
ulence gene expression in S.  aureus, including solonamide B 
(SolB) and synthetic derivatives thereof [7]. Structurally, these 
compounds resemble the native S.  aureus AIPs but competi-
tively interfere with AIP binding to AgrC and inhibit agr [7]. 
Here we used a mouse model to investigate the potential use 
of solonamides to inhibit S. aureus δ-toxin–induced inflamma-
tory responses in S. aureus-colonized skin, demonstrating the 
therapeutic applicability of an antivirulence approach against 
S. aureus-induced skin inflammation.
MATERIALS AND METHODS
Bacterial Strains
LAC, MW2, and their isogenic δ-toxin mutants (Δhld LAC 
and Δhld MW2 where hld gene start codon inactivation abol-
ishes expression without interfering with RNAIII function 
[3]), were cultured in Tryptic Soy Broth (TSB, Oxoid) at 37°C 
overnight. For mast cell degranulation and western blotting, 
wild-type (WT) and Δhld strains were subjected to 10% native 
AIP-containing supernatant, with or without antivirulence 
compounds or nonnative AIP, at time of culture inoculation for 
induction and inhibition of agr, respectively. Bacterial superna-
tants were sterile filtered by passing through 0.2 µm filters.
MC/9 Degranulation Assay
The MC/9 mast cell line was cultured in cRPMI (GIBCO) sup-
plemented with interleukin-3 (IL-3) at 37°C with 5% CO2. 
Degranulation was performed as previously described [5]. 
Β-hexosaminidase release as a measure of mast cell degranulation 
was quantified by measuring absorbance at 405 and 570 nm using 
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the Cytation3 imaging reader (Biotek) and Gen5 software. Results 
of the various stimuli are given as percentages, where freeze and 
thaw of total cell culture represents 100% degranulation.
δ-Toxin Immunoblotting
Bacterial culture supernatants in sample buffer (1:5 ratio in 
20 μL) were loaded on an 18% polyacrylamide gel, run (60 min-
utes at 150 V) and transferred onto a nitrocellulose membrane 
(90 minutes at 25 V). After blocking, the membrane was incu-
bated with shaking overnight at 4°C with primary rabbit-anti-
δ-toxin antibody (1:1000), washed, and further incubated for 
2 hours with secondary antirabbit peroxidase labeled antibody 
(1:5000) [5]. The washed membrane was incubated in ECL mix 
(Biorad), exposed and processed using Image Lab software.
Epicutaneous Colonization of Mice with S. aureus, Treatment with SolB, 
and Endpoint Sampling
The protocol with license number 28-168 27-3 was approved 
by the Chiba University Institutional Animal Care and 
Use Committee. All mice were kept under specific patho-
gen-free conditions and experiments were performed at 
Chiba University in strict accordance with the regulation of 
Animal Experimentation at Chiba University and with the 
national guidelines (Guidelines for Proper Conduct of Animal 
Experiments of the Science Council of Japan).
Six to 12-week-old female BALB/c mice (CLEA Japan) were 
used in sample sizes of 5–10 mice per group. The epicutaneous 
colonization was performed as previously described [5] with the 
exception that no tape stripping was performed. Briefly, over-
night cultures of S. aureus cultured in fresh TSB for 4 hours were 
washed twice and resuspended in PBS at 108 CFU (colony form-
ing units). Bacterial suspension (100 µL) was placed on a patch 
of sterile gauze (1 × 1 cm) and attached to the shaved skin with 
transparent bio-occlusive dressing. For SolB application, coad-
ministration on the patch was performed at 10 ng/100 µL. Each 
mouse was exposed to S. aureus for 1 week and compound was 
readministered every 48 hours by injecting into the gauze. At day 
7 and after visual scoring for disease [5], mice were sacrificed, the 
area under the gauze was excised, and divided into samples for 
CFU, tissue cytokines, histology, and RNA isolation [5].
For all samples, Prism software (GraphPad) was used for 
statistical analyses applying the 2-tailed Mann-Whitney test. P 
values of less than .05 were considered significant.
RESULTS
Solonamides Inhibit δ-Toxin Production and Mast Cell Degranulation 
In Vitro
The δ-toxin of S. aureus is encoded within RNAIII and given 
that we previously have seen dramatic reduction in RNAIII 
expression upon exposure to SolB and derivatives thereof (ESB 
and Am16-L) [8], we examined δ-toxin production by western 
blot in supernatants of treated bacterial cultures. We observed 
that δ-toxin was completely absent in the supernatants of SolB 
and ESB-treated LAC as well as in the supernatant of the con-
trol Δhld LAC strain (Figure 1A), indicating that SolB and ESB 
effectively inhibit δ-toxin production in S. aureus.
To analyze whether reduced δ-toxin production in treated 
cultures also affected mast cells, we measured degranula-
tion of MC/9 cells after stimulation with 10% supernatant of 
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Figure  1. Solonamides inhibit δ-toxin production and mast cell degranulation. A, Immunoblot analysis (20  µL/well) of δ-toxin in overnight culture supernatant of 
Staphylococcus aureus wild-type (LAC WT) alone or treated with 20 µg/mL of the solonamides: solonamide B (SolB), epi-solonamide B (ESB), and the solonamide analogue 
Am16-L. Externally added native autoinducing peptides (AIP1) was included for induction of agr. Culture supernatants of LAC WT treated with compound vehicle (dimethyl 
sulfoxide, DMSO), and supernatant of the δ-toxin mutant strain (Δhld LAC) were included as controls. B, β-hexosaminidase released from MC/9 cells stimulated by medium 
alone (NS), or the same overnight culture supernatants assessed in A. Data represent means ± standard deviation of triplicate cultures. *P < .001 to .05; ns, not significant. 
Both A and B are representative of 3 reproducible independent experiments.
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solonamide-treated LAC. The absence of δ-toxin in treated cul-
ture supernatants correlated with lack of MC/9 degranulation 
activity (Figure  1B). To demonstrate that this effect is down 
to lack of δ-toxin and not to other agr-regulated toxins, we 
performed additional experiments (Supplementary Figure  1) 
where we added nonnative AIP3 (a competitive inhibitor of 
the LAC native AIP1) to agr-active WT and Δhld LAC strains, 
respectively. There was no significant difference between with 
and without AIP3 samples, while the difference between WT vs 
Δhld LAC remained intact, indicating that whether there is an 
active (−AIP3) agr or an inhibited agr (+AIP3) it is the absence 
of the δ-toxin production specifically that inhibits mast cell 
degranulation. Thus, inhibition of RNAIII by the solonamides 
can indeed abolish δ-toxin–induced mast cell degranulation.
Solonamide B Attenuates S.  aureus δ-Toxin–Induced Allergic Immune 
Responses in a Modified Epicutaneous Colonization Mouse Model of 
AD-like Inflammatory Skin Disease
To examine whether solonamides suppress δ-toxin–induced 
disease, we applied a modified epicutaneous disease model for 
AD, in which the skin of BALB/c mice was colonized with LAC 
S. aureus. Here, SolB was added at the time of S. aureus inoc-
ulation, and readministered topically every 48 hours until the 
time of sacrifice (Figure 2A). One week after colonization, the 
mice developed severe inflammation at the site of inoculation 
with pronounced edema, erythema, thickening of the skin, and 
exudate formation (Figure 2B and 2C). Histology of excised tis-
sue from the LAC-colonized skin revealed severe disruption of 
skin morphology, with prominent spongiosis, parakeratosis, and 
infiltration of inflammatory cells (Figure  2C bottom). In con-
trast, mice colonized with LAC but treated with SolB showed a 
significantly reduced skin disease score, a marked decrease in 
skin inflammatory cell infiltrate (Supplementary Figure 2), and 
a much less disrupted skin structure (Figure 2B and 2C) that was 
not due to differences in bacterial load (Figure 2D). Importantly, 
the disease score and histological results of the SolB-treated 
LAC group was almost identical to that presented by the Δhld 
LAC colonized group, suggesting that SolB inhibition of agr 
and consequently RNAIII expression reduces S.  aureus-in-
duced inflammatory responses in vivo, including that towards 
δ-toxin. Quantitative polymerase chain reaction assay on 
lesional skin samples showed that SolB treatment resulted in 
A
C D
B
PBS
•  LAC 108
•  ∆hld LAC 108
•  PBS
•  LAC 108 + compound (10μg/100μL)
Day 0
Inoculation
Day 2 Day 6
Day 7
Sacrifice and Sample
Day 4
LAC LAC + SolB ∆hld LAC
+ compound/DMSO + compound/DMSO
D
is
ea
se
 s
co
re+ compound/DMSO
15
10
PB
S
LA
C
LA
C 
+ 
So
lB
∆h
ld 
LA
C
PB
S
LA
C
LA
C 
+ 
So
lB
∆h
ld 
LA
C
5
***
0
108
107
106
105
104
103
102C
FU
/c
m
2  
(lo
g1
0)
101
100
Figure 2. Solonamide B (SolB) treatment significantly reduces inflammatory skin disease. A, Staphylococcus aureus (LAC; Δhld LAC) colonization and compound treatment 
protocol. BALB/c mice were colonized epicutaneously with 108 colony-forming units of S. aureus using a gauze patch and treated every 48 hours with SolB for 1 week. B, Skin 
disease score 1 week after colonization with δ-toxin mutant (Δhld LAC), wild-type LAC, LAC treated with SolB, and in a control group treated with phosphate-buffered saline 
(PBS). The total clinical score of the skin lesions was designated as the sum of individual scores for 0, 1, 2, and 3 (none, mild, moderate, and severe, respectively) for thick-
ness, erythema, edema, erosion, and scaling [5]. ***P < .001, Mann-Whitney test. C, Skin phenotype and histopathology of BALB/c mice 1 week after treatment with PBS, or 
colonization with Δhld LAC, LAC, or LAC treated with SolB. Skin sections were stained with H & E. Scale bar indicates 100 µm. D, Colony forming units (CFU) of S. aureus in 
excised skin tissue. Representative of 5 to 10 mice per group.
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a 10-fold reduction in RNAIII expression in LAC S.  aureus 
(Supplementary Figure 3), further supporting the evidence for 
in vivo SolB-suppression of RNAIII and subsequent δ-toxin 
production.
Concomitantly, we measured production of cytokines often 
found associated with acute AD, namely members of the IL-1 
and IL-17 family, IL-6, tumor necrosis factor-alpha (TNF-
α), IL-12, interferon-gamma (IFN-γ), and IL-10. In samples 
obtained from lesional skin we found that SolB treatment sig-
nificantly reduced production of only the proinflammatory IL-1 
family (α and β) and IL-6 cytokines, all 3 of which play a central 
role in innate immune responses, with the IL-1 family orches-
trating immune responses to both infections and tissue injury 
[9] (Supplementary Figure 4).
DISCUSSION
Here we provide evidence that an antivirulence approach target-
ing S. aureus agr may attenuate S. aureus-induced inflammation 
in complex disorders of the skin such as AD, by showing that 
SolB, an agr quorum sensing inhibitor, impedes δ-toxin pro-
duction both in vitro and in vivo, resulting in reduced inflam-
mation and better disease outcome without interfering with 
bacterial growth and viability. Many factors contribute to AD, 
such as skin barrier defects, impaired immunity, imbalances 
in skin microbiota, allergens, and bacterial superantigens [10], 
while recent work has also documented a central role of S. aur-
eus colonization and δ-toxin production in severity of the dis-
ease [5]. There exist a number of murine models of atopic skin 
disease available to study each of these factors, for example the 
OVA sensitization model, several transgenic models (IL-3, IL-4 
overexpression), the spontaneous AD Nc/Nga and DS-Ng mod-
els, and the filaggrin-deficient flaky tail mouse model [5, 11]; 
however, the recent link between S. aureus δ-toxin production 
and disease severity was made using the modified epicutane-
ous colonization model [5]. This model has the advantage that, 
unlike others that rely on subepidermal inoculation or epicu-
taneous colonization after physical disruption of the epidermis 
(eg, by tape stripping), any inflammation observed is solely in 
response to S. aureus colonization [11].
SolB treatment not only reduced inflammatory cell infiltrates 
at the site of S. aureus colonization, but also resulted in a signifi-
cant drop in the production of proinflammatory cytokines IL-1α, 
IL-1β, and IL-6. In AD, IL-1α, IL-1β, and IL-6 cytokine levels are 
statistically higher than in healthy individuals and contribute to 
the robust T helper 2 (TH2) response seen in the acute phase of 
AD [9, 12]. Interestingly, this significant drop was not observed 
in the Δhld LAC group, implying that SolB has an impact on the 
inflammatory response in addition to that due to interference with 
δ-toxin expression. We have previously shown that SolB reduces 
the transcription of the psma operon (encoding the PSMα vir-
ulence peptides under strict regulation of agr), due to reduced 
expression of agrA [7]. These observations, as well as those of 
others, that δ-toxin and PSMα are potent inducers of IL-18 
(another key mediator of skin inflammation) production from 
keratinocytes [13], suggest that other agr-regulated virulence fac-
tors also modulate skin inflammation. Further supporting this is 
the recent finding that PSMα induces release of IL-1α from kerati-
nocytes in the same murine epicutaneous model used in this study. 
This IL-1α release, together with IL-36α, results in corresponding 
receptor signaling and induction of IL-17–producing cells that are 
key mediators of skin inflammation [14]. Interestingly, in another 
study looking at epicutaneous versus intradermal challenge 
with S. aureus in an AD murine model [15], an IL-36–mediated 
response by keratinocytes took precedence over that of IL-1α and 
IL-18, which were instead observed following intradermal chal-
lenge. In the same study, PSMα and not δ-toxin appeared to be the 
main inflammation driver [15]. These results imply that S. aureus 
skin inflammation in the context of atopic-like disease is compli-
cated and warrants further investigations.
In summary, we hypothesize that SolB effectively targets 
multiple S.  aureus-induced inflammatory responses and in 
turn dampens TH2-type skin inflammation, so common in an 
atopic setting, by blocking mast cell degranulation and interfer-
ing with IL-1α and IL-36 skin inflammatory responses. As the 
solonamides have been reported to be nontoxic towards murine 
and human immune cells, this group of compounds may poten-
tially be safe as antivirulence therapeutics [8] and beneficial for 
the treatment of inflammatory symptoms related to epicutane-
ous S. aureus colonization in AD.
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